Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium
Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note,...
423 Views
Jiangsu Hengrui Pharma A/H Listing - Recent Updates and Thoughts on A/H Premium
The company has now filed its PHIP and is said to be pre-marketing with an aim to launch the deal in the coming week. Although it would have to...
706 Views
HONG KONG ALPHA PORTFOLIO (April 2025)
The Hong Kong Alpha portfolio underperformed its benchmark index during April by 1.1%. Since its inception last year, the portfolio has...
522 Views
Hong Kong Buybacks Weekly (Apr 17th): AIA, Tencent, Wuxi Biologics
We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were AIA (1299 HK),...
299 Views
WuXi AppTec (2359 HK): In-Line 2024 Performance; Announces Dividend and A Share Buyback Plan
1Q25 resumes double-digit growth, with revenue growing 21% YoY and net profit increasing 40% YoY. Growth was driven by Wuxi Chemistry segment. U.S....
599 Views